

November 3-5, 2026 | Boston, MA
www.dermatology-drugdevelopment.com

REGISTER BY
FRIDAY, JULY 17
TO SAVE UP TO
\$1000




10TH ANNIVERSARY

Dermatology Drug Development Summit

Discovering, Developing & Commercializing Next-Generation Inflammatory Skin Disease Therapeutics

**Deciphering Disease Heterogeneity,
Optimizing Dosing Regimens & De-Risking
Emerging Targets to Transform Long-Term
QoL & Address Unmet Needs Across Rare
& Common Inflammatory Skin Disease**

Expert Speakers Include:



Lotus Mallbris
Senior Vice
President, Business
Unit & Immunology
Leader
Eli Lilly



Xuqiu Lei
Senior Scientist,
Discovery
Immunology
Merck



**Kumar
Krishnaswamy**
Scientific Director
AbbVie



Lily Lee
Vice President &
Head of Global
Medical Strategy
& Therapeutic
Dermatology
Galderma



Kim Kjoller
Chief Executive
Officer
UNION Therapeutics



Mudgal Kothehar
Vice President,
Clinical Development
SUN Pharma

Proud to Partner With:



Discovering, Developing & Commercializing Next-Generation Inflammatory Skin Disease Therapeutics

10th ANNIVERSARY
Dermatology Drug Development Summit
November, 3-5, 2026 | Boston, MA

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTRATION

Competition is heating up across the dermatology treatment landscape, as a new wave of next-generation interleukin inhibitors from the likes of **Pfizer**, **Corvus Therapeutics**, **Nektar Therapeutics**, and **Apogee Therapeutics** push to demonstrate meaningful differentiation and optimized dosing regimens over marketed products. Moreover, growing unmet needs for more efficacious and targeted therapies are fueling momentum around emerging targets like TYK2 and STAT6, while major players including **Novartis** and **Almirall** invest millions into AI-powered discovery.

Yet, with ongoing challenges spanning multifactorial target involvement, translational de-risking and the need to secure earlier-stage investment, these issues remain front and center for the **90+** discovery, preclinical, clinical and medical industry leaders set to unite at this year's **10th Dermatology Drug Development Summit**.

- Discover novel approaches beyond IL- and JAK- inhibition and optimize how new targets are interrogated within in vivo inflammatory skin disease models
- Demonstrate efficacy amid prevalent placebo responses, streamline severity measurements like scar staging, and stratify by potential high responders
- Innovate more targeted skin delivery systems and longer-lasting oral, topical, and injectable formulations
- Establish new market entrants that demonstrate comparative advantage against a sea of competitors
- De-risk earlier investment opportunities through more rigorous evidence generation and evaluate a growing landscape of inflammatory skin conditions beyond AD and Psoriasis

Returning with two tracks of content to deliver deeper insight across discovery, preclinical, clinical and commercial strategy, don't miss your chance to connect with leading minds from **Galderma**, **AbbVie**, **Eli Lilly**, **Merck**, **SUN Pharma**, **UNION Therapeutics**, and more as they seek to discover, develop and commercialize the next wave of precision therapeutics for AD, Psoriasis, HS, Alopecia, Vitiligo and more.

What Our Past Attendees have to Say

“The Dermatology Drug Development Summit provides an opportunity to engage in in-depth, scientifically grounded discussions on the evolving treatment landscape for inflammatory skin diseases. The program facilitates meaningful exchange on emerging mechanisms, therapeutic innovation, and clinical translation, with focused sessions addressing key development challenges in areas such as immune modulation, barrier dysfunction, and chronic inflammation”

**Chief Executive Officer,
Shaperon**

Key Benefits of Attending



Discover novel therapeutic approaches beyond IL- and JAK- inhibition to unlock the next generation of inflammatory skin disease therapies with **Merck**, **AbbVie** and **First Tracks Biotherapeutics**




Optimize translational success through biomarkers, patient stratification, AI-enabled discovery tools and next-generation modalities with **Engimmune Therapeutics** and **AOBiome**



Differentiate dermatology assets through smarter dosing strategies, advanced delivery systems and earlier intervention approaches with **Galderma** and **Kalm Therapeutics**



Overcome clinical development challenges including placebo response, endpoint selection, global trial variability and responder identification with **UNION Therapeutics** and **Enveda Biosciences**



Strengthen investment cases, commercialization strategies and competitive positioning in an increasingly crowded dermatology landscape with **Nielsen Bio** and **WestPark Capital**

New for 2026: Greater Indication Diversity & Double the Content

10th ANNUAL
Dermatology Drug Development Summit
November, 3-5, 2026 | Boston, MA

As the dermatology landscape continues to evolve beyond its traditional focus on Atopic Dermatitis and Psoriasis, the **10th Dermatology Drug Development Summit** is expanding both the breadth of indications covered and the depth of scientific discussion available to attendees.

Alongside extensive coverage of the industry's largest markets, this year's agenda introduces dedicated content spanning **Hidradenitis Suppurativa, Epidermolysis Bullosa, Vitiligo, Acne, Alopecia Areata, Molluscum Contagiosum, Prurigo Nodularis, wound healing, skin aging** and **additional ultra-rare inflammatory skin disorders**, creating new opportunities to benchmark emerging science, identify future growth areas and inform portfolio strategy.

Key Sessions not to Miss

abbvie



Workshop A | Hidradenitis Suppurativa: Driving Earlier Intervention & Unlocking Disease Modification in HS to Improve Long-Term Outcomes with AbbVie, Navigator Medicines & Affibody

1

abbvie



Panel Discussion: Competing Beyond Dupixent: Leveraging Unique Mechanisms of Action & Long-Acting Drugs to Differentiate in the Next Wave of Atopic Dermatitis Therapeutics with AbbVie, Engimmune, Therapeutics & Galderma

2



Advancing Precision Immunology in Vitiligo: Positioning CXCL10 Therapies to Move Beyond Symptom Management with Edesa Biotech

3



Advancing Disease-Modifying Therapies in Epidermolysis Bullosa Simplex to Move Beyond Wound Management & Restore Structural Integrity with Mariposa Therapeutics

4



Why Some Dermatology Programs Become Billion-Dollar Franchises While Others Disappear with WestPark Capital

5

New Companies for 2026



enveda®



Showcase Your Scientific Poster



Contribute to the conversation and share your cutting-edge research with your fellow dermatology community to showcase your breakthrough discoveries to a vast audience of experts.

You must register your place in order to submit an abstract for review to showcase your poster*

*Please visit the website for the T&Cs for presenting a poster

Your Expert Speakers

10th ANNIVERSARY
Dermatology Drug
Development Summit

November, 3-5, 2026 | Boston, MA

Pharma Leaders Driving Discovery to Commercial Strategy



Vanessa Morales-Tirado
Principal Research Scientist I
AbbVie



Kumar Krishnaswamy
Scientific Director
AbbVie



Suryasarathi Dasgupta
Director, Scientific & Precision Medicine Immunology
AbbVie



Lotus Mallbris
Senior Vice President, Business Unit & Immunology Leader
Eli Lilly



Akanksha Mittal
Head of Medical Affairs & Immunology
Galderma Laboratories



Lily Lee
Vice President & Head of Global Medical Strategy & Therapeutic Dermatology
Galderma Laboratories



Nathalie Wagner
Head of Preclinical Pharmacology
Galderma International



Xuqiu Lei
Senior Scientist, Discovery Immunology
Merck



Mudgal Kothekar
Vice President, Clinical Development
Sun Pharma

Biotech Innovators Advancing Next-Generation Skin Therapies



Patricia Giblin
Chief Scientific Officer
Ability Biologics



Maria Akerman
Director, Global Programs
Affibody



Michael Jacobson
Chief Executive & Scientific Officer
Alnivo Therapeutics



Neal Koller
Chairman of Directors & Chief Executive Officer
Alphyn Biologics



Hyun Kim
Senior Vice President, Clinical Development
AOBiome



Dan Brownell
Senior Director, Research & Development
AOBiome



Karen McGuire
Chief Executive Officer
BioMendics



Alex Nivorozhkin
Founder, Director
C-Click Life Science



Par Nijhawan
Chief Executive Officer & Co-Founder
Edesa Biotech



Kenneth Crook
Head of Translational Medicine
Engimmune Therapeutics

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTRATION

Your Expert Speakers

10th ANNIVERSARY
Dermatology Drug Development Summit

November, 3-5, 2026 | Boston, MA



Jose Trevejo
Chief Medical Officer
Enveda Biosciences



Paul Lizzul
Chief Medical Officer
First Tracks Biotherapeutics



Michael Howell
Co-Founder
Galileo Biosystems



Anuj Singhal
Chief Executive Officer
Kalm therapeutics



David Howat
Chief Executive Officer
Mariposa Therapeutics



Kristie Grebe
Chief Scientific Officer
Navigator Medicines



Christoph Wulf
Vice President & Head
of Commercial
Nielsen BioSciences



Apostolos Pappas
Chief Scientific Officer
Nogra Pharma



Mary Spellman
Chief Medical Officer
Panclarity



Frederick Beddingfield
Chief Executive Officer
& Director
Rubedo Life Sciences



Kim Kjoeller
Chief Executive Officer
UNION therapeutics

Academics & Investors Translating Science into Clinical Impact



Karl Koehler
Associate Professor &
Head, Neck Surgery &
Otolaryngology
Harvard Medical School



John Armstrong
Managing Director
Westpark Capital

Partners Powering End-to-End Drug Development Execution



Harald Schnidar
Chief Executive Officer
Scarletred

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTRATION

Pre-Conference Workshop Day

TUESDAY, NOVEMBER 3

Check-in & Light Breakfast

8.00 - 9.00

Workshop A

9.00 - 12.00

Hidradenitis Suppurativa: Driving Earlier Intervention & Unlocking Disease Modification in HS to Improve Long-Term Outcomes

Hidradenitis Suppurativa (HS) remains one of the most challenging inflammatory skin diseases to diagnose, treat, and manage long term. While therapeutic innovation in dermatology continues to accelerate, HS still faces significant unmet need, including delayed diagnosis, irreversible tissue damage, limited biomarkers, and comparatively slow translational progress. This workshop will explore how earlier intervention strategies and emerging therapeutic approaches could shift HS management beyond reactive symptom control toward improving long-term outcomes and potentially modifying disease progression.

Attendees will gain insight into the evolving HS treatment landscape, the scientific and clinical barriers slowing progress, and what is needed to strengthen translational development in this underserved area of inflammatory disease.

Key Questions to be Addressed:

- How can earlier intervention influence long-term disease progression and tissue damage in HS?
- What evidence is needed to support earlier use of advanced therapies in HS care pathways?
- Why has HS seen comparatively limited preclinical and translational advancement compared with other inflammatory diseases?
- What lessons can HS learn from earlier biologic intervention strategies used in psoriasis, atopic dermatitis, and other chronic inflammatory conditions?
- How can the field move beyond symptom management toward disease modification and improved quality of life for patients living with HS?



Vanessa Morales-Tirado
Principal Scientist, Research
AbbVie



Kristie Grebe
Chief Scientific Officer
Navigitor Medicines



Maria Akerman
Director, Global Programs
Affibody

Lunch & Networking Break

12.00 - 1.00

■ The high quality and accessibility of the participants, both speakers and attendees, and the networking opportunities. The breaks were long enough to meet other participants and have productive conversations. The size of the conference was just right - small enough to be intimate and not overwhelming but large enough to meet many people. ■

Chief Executive Officer & Chief Scientific Officer, **Alnivo Therapeutics**

Pre-Conference Workshop Day

TUESDAY, NOVEMBER 3

Workshop B

1:00 - 4:00pm

Rare & Ultra-Rare Inflammatory Skin Disease: Exploring Under-Researched Populations to Address High Unmet Need & Unlock Scalable Innovation

Despite rapid expansion across mainstream inflammatory indications, many rare and under-researched cutaneous disorders continue to face limited therapeutic innovation, poor translational models, delayed diagnosis and minimal investment attention. This workshop will explore development opportunities across indications including alopecia areata, androgenetic alopecia, severe acne subtypes, pigmentary disorders such as melasma and vitiligo, dermal drug reactions and other niche inflammatory and fibrotic conditions where unmet need remains high despite significant patient burden.

Attendees will discuss how developers can prioritise underserved indications, generate meaningful translational evidence in small patient populations, and build scalable strategies that translate rare disease insights into broader platform and pipeline opportunities.

Key Objectives:

- Why are rare and under-researched cutaneous indications becoming increasingly attractive for developers and investors?
- How can companies overcome challenges in diagnosis, patient stratification and patient identification across heterogeneous and underserved populations?
- What translational, biomarker and clinical evidence is required to demonstrate value in smaller populations with limited historical research?
- How can success in niche indications such as Lichen Sclerosus, Vitiligo, Pemphigoid Nodularis, Prurigo Nodularis, Pyoderma gangrenosum or Generalized Pustular Psoriasis inform broader therapeutic development across chronic inflammatory and regenerative disease?
- What are the key scientific, operational and commercial risks when developing therapies in smaller and historically overlooked patient populations?



Akanksha Mital
Global & US Medical Affairs
Leader
Galderma



Mary Spellman
Chief Medical Officer
Panclarity



Karen McGuire
Chief Executive Officer
BioMendix

End of Pre-Conference Workshop Day

4.00

“Firstly, a great program well put together, with leading academic and pharma participants that made this a cutting-edge meeting. I found much of the content very valuable and educational. Additionally, the mix of presentations, panel discussions and fireside chats provided value and insights beyond a more regular research meeting”

Senior Director, Immunology & Inflammation, **Schrodinger**

Conference Day One

Wednesday, November 4

7:30 Check In, Coffee & Light Breakfast

8:25 Chair's Opening Remarks



Harald Schnidar
Chief Executive Officer
Scarletred

Differentiating Next-Generation Therapies Through Novel Pathways, Precision Targeting & Improved Durability

8:30 **Panel Discussion: Targeting Novel Pathways Beyond IL & JAK Inhibitors to Differentiate Therapies & Expand Treatment Options**

- Exploring novel biological pathways beyond established mechanisms, unlocking new therapeutic angles, to differentiate pipelines in a crowded market
- Validating emerging targets with translational data, reducing scientific uncertainty, to increase success rates in development
- Expanding modality and pathway diversity, broadening treatment options, to address unmet patient needs



Xuqiu Lei
Senior Scientist, Discovery Immunology
Merck



Paul Lizzul
Chief Medical Officer
Anaptys Biosciences



Kumar Krishnaswamy
Scientific Director
AbbVie

9:00 Session Reserved for SCARLETRED



9:30 **Panel Discussion: Competing Beyond Dupixent: Leveraging Unique Mechanisms of Action & Long-Acting Drugs to Differentiate in the Next Wave of Atopic Dermatitis Therapeutics**

- Positioning new mechanisms of action such as IL-31 inhibition and long-acting drugs as a potentially best-in-class alternative in moderate-to-severe atopic dermatitis
- Assessing how infrequent maintenance dosing compares with Dupixent, Ebglyss and oral JAK inhibitors, improving convenience and long-term adherence potential, to strengthen differentiation in an increasingly crowded AD market
- Understanding whether deeper and sustained responses with highly selective IL-13 blockade can redefine competitive benchmarks for efficacy, safety and patient preference, aligning clinical outcomes with payer and physician expectations, to maximise uptake and commercial value ahead of planned Phase 3 initiation in 2H 2026



Vanessa Morales-Tirado
Principal Scientist, Research
AbbVie



Kenneth Crook
Head of Translational Medicine
Engimmune Therapeutics



Akanksha Mital
Global & US Medical Affairs Leader
Galderma

10:00 Speed Networking

A prime chance to make the most of in-person networking and forge new connections as new companies enter and existing ones broaden their presence within the dermatology space. This is designed to maximize your exposure to a wide range of new individuals and serve as a catalyst for ongoing discussions throughout the summit.

10:45 Morning Break & Refreshments

TRACK ONE: DISCOVERY & PRECLINICAL

TRACK TWO: CLINICAL & COMMERCIAL Harald Schneider, Chief Executive Officer, Scarletred

Strengthening Translational Confidence in Dermatology: Building More Predictive Models & Learning from Clinical Outcomes to Improve Discovery Decisions

Optimizing Therapeutic Performance in Dermatology: Advancing Dosing, Delivery & Multi-Mechanistic Approaches to Maximize Clinical Impact

11.00 Building Predictive Human-Relevant Skin Models to Improve Translational Confidence & Accelerate First-in-Human Readiness

- Developing ex vivo, in vitro and chip-based skin models, improving human relevance, to strengthen confidence before clinical translation
- Testing emerging modalities in engineered model systems, capturing delivery, target engagement and tissue response, to reduce uncertainty before dose selection
- Learning from model innovation to benchmark advanced platform approaches, and improve preclinical decision-making across difficult dermatology questions

Karl Koehler, Associate Professor & Head of Neck Surgery & Otolaryngology, Department of Dermatology, **Harvard Medical School**

11.00 Optimizing Dosing Strategies to Enhance Efficacy & Differentiate Dermatology Therapies

- Explain how model-informed drug development (MIDD) approaches, integrating clinical data and quantitative pharmacology methodologies, were applied to support dose selection for nemolizumab in 2 different indications
- Demonstrate the role of body weight as a key intrinsic covariate influencing the PK profile of nemolizumab, and how this finding informed the implementation of a body weight-tiered dosing strategy in Prurigo Nodularis versus a fixed dosing regimen in Atopic Dermatitis

Nathalie Wagner, Head of Clinical Pharmacology, **Galderma**

Conference Day One

Wednesday, November 4

11.30 Roundtable Discussion: Back-Translating Clinical Readouts into Discovery Workflows to Improve Model Relevance & Target Selection

- Interpreting clinical failures and efficacy ceilings in HS, AD and psoriasis, revealing which preclinical assumptions did or did not translate, to refine future target validation strategies
- Connecting patient pathology with animal, in vitro and tissue-based models, clarifying what each model truly represents, to avoid overinterpreting contrived systems
- Applying learnings from IL-17, IL-23, TNF, IL-1, JAK and OX40L programs, identifying pathway-specific translational gaps, to prioritise more clinically relevant discovery work

Dan Brownell, Senior Director, Research & Development, AOBiome

11.30 Moving Beyond Single-Target Therapies: Clinical Development Insights from a Multi-Target Platform in Atopic Dermatitis & Molluscum Contagiosum

- Exploring how multi-mechanistic therapeutics may address complex disease biology more effectively than conventional single-target approaches
- Reviewing pharmacokinetic, mechanistic and translational learnings supporting development across inflammatory and infectious dermatological conditions
- Discussing Phase 2 clinical development strategies and cross-indication insights to accelerate future applications of multi-target therapeutics

Neal Koller, Chairman of Directors & Chief Executive Officer, Alphyn Biologics

12.00 Advancing Delivery Systems to Improve Patient Experience & Enhance Therapeutic Impact

- Exploring innovative delivery systems, improving usability, to increase patient adherence
- Enhancing drug delivery performance to maximize efficacy and improve outcomes
- Differentiating therapies through formulation, strengthening positioning, to gain competitive advantage

Anuj Singhal, Chief Executive Officer, Kalm Therapeutics

12.30 Lunch & Networking Break

Discovering the Next Generation of Dermatology Targets: Leveraging Novel Biology, Translational Science & Precision Immunology to De-Risk Innovation

1.30 Targeting Inflammation at the Source: Advancing ENGI-004 to Deliver Tissue-Selective Immune Modulation in Atopic Dermatitis

- Exploring a novel tissue-targeted approach to immunomodulation by engaging MHC-related receptors enriched at barrier tissues, including the skin, to concentrate activity where disease occurs
- Leveraging AI-guided protein engineering to optimize efficacy and safety through precise delivery of inhibitory signals to inflamed tissues while minimizing systemic immune suppression
- Translating ENGI-004 from discovery toward clinical development to establish a differentiated therapeutic strategy for atopic dermatitis and other barrier tissue inflammatory diseases

Kenneth Crook, Head of Translational Medicine, Engimmune Therapeutics

Redefining Topical Dermatology: Advancing Novel Mechanisms & Clinical Strategies to Deliver Meaningful Differentiation in Acne & Alopecia Areata

1.30 Raising the Bar in Alopecia Areata: Positioning Next-Generation Topical Therapies to Deliver Meaningful Hair Regrowth in a JAK-Dominated Market

- Examining why previous topical approaches have struggled in alopecia areata, identifying key biological, formulation and clinical development challenges, to inform the next generation of topical therapies
- Defining meaningful clinical differentiation beyond oral JAK inhibitors, evaluating efficacy, durability, safety and patient preference considerations, to establish where topical therapies can create value in an increasingly competitive treatment landscape
- Optimizing clinical trial design and endpoint selection for topical agents, addressing unique development challenges around efficacy assessment, patient selection and long-term treatment expectations, to improve the likelihood of clinical and regulatory success

Mudgal Kothekar, Vice President, Clinical Development, SUN Pharma

Conference Day One

Wednesday, November 4

2.00 From Ocean Biology to Dermatology Therapeutics: Using Translational Science to Identify Biomarkers, Validate Targets & Accelerate Drug Discovery

- Applying translational medicine approaches to uncover novel biomarkers and therapeutic pathways, transforming biological observations into validated targets for inflammatory skin disease
- Exploring how mechanistic insights into oxidative stress, immune regulation and tissue homeostasis can strengthen target selection, increasing confidence in emerging pathways such as AHR before clinical development
- Sharing lessons from translating novel biological discoveries into dermatology drug candidates, demonstrating how early biomarker characterization can reduce development risk and improve the probability of clinical success

Michael Howell, Co-Founder, **Galileo Biosystems**

2.00 Phase III-Ready Topical PPAR γ Modulator for Moderate-to-Severe Acne

- Novel first-in-class topical PPAR γ modulator designed to target multiple acne pathways simultaneously, including inflammation, sebogenesis and keratinocyte dysfunction
- Phase IIb study in 450 patients demonstrated significant reductions in total lesion count and improved Investigator Global Assessment (IGA) success rates with a favourable safety and tolerability profile
- Phase III-ready programme with FDA and EMA-aligned development plans, positioning NAC-GED-0507 as a potential first new mechanistically differentiated topical acne therapy in decades

Apostolos Pappas, Chief Scientific Officer, **Nogra Pharma**

2.30 Afternoon Break & Refreshments

Accelerating Dermatology Innovation: Leveraging AI, Precision Medicine & Smarter Development Strategies to Build More Competitive Pipelines

3:00 Redefining the Oral Psoriasis Market: Positioning Next-Generation TYK2 Inhibitors to Compete with Biologics on Efficacy, Convenience & Durability

- Demonstrating biologic-like PASI 90 and PASI 100 responses from a once-daily oral TYK2 inhibitor, to position next-generation oral therapies against injectable standards of care
- Assessing rapidity, durability and complete skin clearance outcomes across TYK2 programs, clarifying what level of efficacy is now required for differentiation in psoriasis, to strengthen competitive positioning in an increasingly crowded inflammatory dermatology market
- Understanding how regulators, physicians and payers may evaluate highly selective oral TYK2 inhibition versus established biologics and oral competitors such as Otezla and Sotyktu, aligning clinical development with commercial expectations, to maximize uptake, reimbursement and long-term franchise value



Suryasarathi Dasgupta
Director - Scientific & Precision Medicine Immunology
AbbVie

3:30 Session Reserved for Quantifcare



3:45 From 140 Million Cells to Human Trials: Applying AI & Human Tissue Biology to Accelerate Dermatology Drug Discovery

- Building proprietary cellular atlases through advanced multi-omics approaches to reveal novel disease mechanisms and therapeutic opportunities
- Leveraging AI and machine learning to identify, prioritize and validate targets emerging from complex human biology datasets
- Sharing lessons from advancing an AI-discovered therapeutic from target identification to clinical studies in approximately half the traditional development timeline



Frederick Beddingfield
Chief Executive Officer & Director
Rubedo Life Sciences

4:15 Session Reserved for Legit Health



Conference Day One

Wednesday, November 4

4:25

Accelerating Time to Proof-of-Concept to De-Risk Dermatology Pipelines & Unlock Faster Decision-Making

- Reducing time to proof-of-concept through optimized early study design, enabling faster signal detection, to accelerate go/no-go decisions and reduce R&D spend
- Identifying tools to detect early efficacy signals in large patient cohorts, improving trial efficiency, to minimize costly late-stage failures
- Streamlining development pathways for systemic and early-stage assets, enhancing operational speed, to bring therapies to patients faster



Patricia Giblin
Chief Scientific Officer
Ability Bio

4:55

Chair's Closing Remarks



Harald Schnidar
Chief Executive Officer
Scarletred

5:00

Scientific Poster Session

This is an informal session to help you connect with your peers in a relaxed atmosphere to continue forging new and beneficial relationships. With an audience of immunology experts eager to hear the latest discoveries in dermatology therapeutic research, you will have the opportunity to display a poster presenting your own work and innovations. Don't miss out on the chance to connect, learn, and present.

■ ■ Great presentations from existing market leaders as well as up and coming drug developers ■ ■

Senior Director, Research & Development, **AOBiome**

■ ■ I enjoyed the intimate gathering of derm biotech leaders, and the many opportunities to network and connect ■ ■

Chief Scientific Officer & Co-Founder, **Noa Therapeutics**

■ ■ I really enjoy how easy it is to network at the Hanson Wade conferences. I genuinely feel like each attendee welcomes being approached, and I made some valuable connections ■ ■

Senior Scientist, **Apogee Therapeutics**

Conference Day Two

Thursday, November 5

8:00 Check In, Coffee & Light Breakfast

8:55 Chair's Opening Remarks



Harald Schnidar
Chief Executive Officer
Scarletred

Addressing Underserved Patient Needs Through Novel Science & Emerging Therapeutic Strategies

9:00 **Panel Discussion: Bringing Cosmetic Dermatology Back into R&D & Addressing High Patient Demand Through Scientific Innovation**

- Examining why conditions such as acne, female hair loss, skin aging and aesthetic restoration remain underrepresented in dermatology drug development, despite affecting millions of patients worldwide, to identify where innovation is most needed
- Exploring how advances in regenerative medicine, longevity science, muscle restoration, skin rejuvenation and hair biology are creating new opportunities beyond traditional inflammatory dermatology, to unlock the next generation of dermatology pipelines
- Debating how industry, academia and clinicians can elevate cosmetic dermatology from a procedure-driven market to a science-led therapeutic field, strengthening evidence generation, regulatory pathways and investment in high-unmet-need patient populations



Lotus Mallbris
Senior Vice President, Business Unit Leader, Immunology
Eli Lilly



Michael Jacobson
Chief Executive & Scientific Officer
Alinvo Therapeutics



Frederick Beddingfield
Chief Executive Officer & Director
Rubedo Life Sciences

9:30 Session Reserved for CHDR



10:00 **Raising the Efficacy Bar in Hidradenitis Suppurativa: Translating Phase 1 Data for Dual OX40L/TNF α Inhibition into the Next Generation of Disease Control**

- Evaluating the clinical rationale for simultaneous OX40L and TNF α inhibition to address multiple inflammatory pathways driving HS pathogenesis and disease heterogeneity
- Reviewing Phase 1 safety, tolerability and pharmacokinetic findings supporting further development and potential once-monthly dosing in patients with HS
- Exploring how bispecific antibody approaches could improve upon TNF α monotherapy to deliver more durable responses and raise the standard of care in moderate-to-severe HS



Kristie Grebe
Chief Scientific Officer
Navigator Medicines

10:30 Session Reserved for QIMA Life Sciences



10:40 Morning Break & Refreshments

Conference Day Two

Thursday, November 5

TRACK ONE: DISCOVERY & PRECLINICAL

Advancing Disease-Modifying Therapies Through Smarter Molecule Design, Translational Strategy & Development Planning

11.30 Advancing Disease-Modifying Therapies in Epidermolysis Bullosa Simplex to Move Beyond Wound Management & Restore Structural Integrity

- Targeting the underlying keratin dysfunction driving Epidermolysis Bullosa Simplex, restoring functional intermediate filament integrity rather than managing downstream symptoms, to shift treatment approaches from palliation toward true disease modification
- Exploring small-molecule strategies designed to rescue skin resilience at the cellular level, preventing blistering and mechanical fragility across EBS subtypes, to improve long-term mobility, wound burden and quality of life
- Building translational and regulatory pathways for first-in-class structural rescue therapies in rare disease, aligning patient need, biomarker development and early clinical strategy, to accelerate meaningful innovation in underserved genetic conditions

David Howat, Chief Executive Officer, **Mariposa Therapeutics**

12.00 Roundtable Discussion: Designing Safer Molecules & Feasible Formulations Earlier to Reduce Off-Target Risk & Improve Development Viability

- Using AI, big data and in silico design to predict receptor selectivity, reducing unexpected off-target effects, to improve confidence before costly clinical investment
- Assessing systemic exposure, metabolite risks and tissue-specific safety liabilities, anticipating unpredictable toxicities, to avoid late-stage failures seen with dermatology standards such as retinoic acid
- Balancing sophisticated formulation design with manufacturability and cost, ensuring preclinical innovation remains commercially viable, to support realistic pipeline progression

12.30 Lunch & Networking Break

Finding the Right Biology, Patient & Indication: Improving Early Development Decisions to Maximize Therapeutic Potential

1.30 Unlocking the Endocannabinoid System in Dermatology: Advancing Cannabinoid-Based Therapeutics Across Inflammation, Barrier Dysfunction & Wound Repair

- Examining the biological role of CB1, CB2 and endocannabinoid signaling pathways in skin homeostasis, inflammation and tissue repair, identifying opportunities for therapeutic intervention across dermatological disorders
- Reviewing emerging preclinical and translational evidence supporting cannabinoid-targeted approaches in inflammatory skin disease, wound healing and barrier restoration, to evaluate where meaningful clinical signals may be achieved
- Leveraging dermatology as an efficient proof-of-concept setting for cannabinoid drug development, using accessible tissues and topical delivery strategies to accelerate human translation and de-risk broader development programs

Alex Nivorozhkin, Founder, Director, **C-Click**

TRACK TWO: CLINICAL & COMMERCIAL

Harald Schneider, Chief Executive Officer, **Scarletred**

Targeting the Root Cause of Disease: Applying Precision Biology to Transform Rare & High-Unmet-Need Dermatology Indications

11.30 Leveraging mTOR Inhibition to Restore Keratinocyte Homeostasis Across Rare Monogenic Skin Disorders

- Identifying shared pathological mechanisms across monogenic keratin disorders through translational research and patient-derived models
- Evaluating mTOR inhibition as a strategy to restore cellular homeostasis and improve disease outcomes across genetically distinct indications
- Leveraging cross-indication biology to create scalable development pathways in ultra-rare dermatology populations

Karen McGuire, Chief Executive Officer, **BioMendix**

12.00 Advancing Precision Immunology in Vitiligo: Positioning CXCL10 Therapies to Move Beyond Symptom Management

- Evaluating CXCL10 in vitiligo, targeting tissue-resident memory T cells driving depigmentation, to advance more durable and disease-modifying approaches beyond current standard-of-care therapies
- Assessing how CXCL10 compares with JAK inhibitors and phototherapy approaches, addressing limitations around chronic use, safety and relapse, to differentiate next-generation vitiligo pipelines in an underserved market
- Understanding growing investor confidence in dermatology innovation, accelerating development in high-unmet-need autoimmune skin disease, to strengthen the commercial outlook for emerging vitiligo therapeutics

Par Nijhawan, Chief Executive Officer, **Edesa Biotech**

Optimizing Dermatology Trial Design to Reduce Variability, Accelerate Readouts & Improve Development Decisions

1.30 Using Skin Biomarkers to Address Placebo Response & Endpoint Variability to Improve Signal Detection in AD, HS & Psoriasis Trials

- Understanding rising placebo responses across EASI, IGA and HiSCR-based assessments, reducing interpretive noise, to improve confidence in whether an active therapy is truly effective or underpowered by endpoint variability
- Integrating objective measures such as tape stripping, blood biomarkers, imaging and AI-enabled lesion assessment, capturing earlier biological activity and target engagement, to strengthen early efficacy readouts and support go/no-go decision-making
- Designing trials around disease heterogeneity and patient fluctuation patterns, distinguishing chronic from rapid-cycling disease activity, to reduce placebo interference, improve endpoint timing and increase the likelihood of demonstrating meaningful treatment benefit

Kim Kjoller, Chief Executive Officer, **UNION Therapeutics**

Conference Day Two

Thursday, November 5

2.00 Roundtable Discussion: Identifying the Right Indications to Maximize Signal Detection & Accelerate Development Success

- Pinpointing optimal indications for early assets, increasing signal detection likelihood, to accelerate proof-of-concept
- Aligning indication selection with biology, improving relevance, to enhance success rates
- Prioritizing high-impact indications, maximizing ROI, to drive pipeline efficiency

2.00 Standardizing Global Clinical Trial Conduct to Reduce Operational Variability & Improve Cross-Regional Data Reliability

- Addressing inconsistencies in investigator assessment, adverse event reporting and site conduct across global trial regions, improving operational standardization, to strengthen confidence in safety and efficacy comparisons across multinational studies
- Enhancing site training, oversight and endpoint execution in inflammatory disease trials, reducing investigator-dependent variability and reporting bias, to improve reproducibility across expanding global trial networks
- Balancing increasingly complex biomarker and mechanistic data collection with site and patient burden, streamlining operational workflows and sample logistics, to maintain scalable, executable and regulator-ready study designs

Jose Trevejo, Chief Medical Officer, **Enveda Biosciences**

2.30 Afternoon Break & Refreshments

Strengthening Investment, Differentiation & Commercial Positioning to Compete in the Next Era of Dermatology Innovation

3:00 Improving Evidence Generation to Strengthen Investment Cases & Accelerate Development

- Building robust evidence packages and aligning with investor expectations to secure funding
- Addressing early-stage uncertainties, reducing perceived risk, to unlock investment
- Aligning data with commercial outcomes, strengthening positioning, to drive pipeline progression
- Evolution of endpoints



Lily Lee
Vice President & Head of Global Medical Strategy & Therapeutic Dermatology
Galderma

3:30 Establishing New Market Entrants to Compete Effectively & Drive Adoption

- Developing strategies for market entry, reducing launch barriers, to accelerate uptake
- Differentiating products in competitive landscapes, enhancing visibility, to win market share
- Overcoming adoption challenges, aligning with stakeholder needs, to drive commercial success



Christoph Wulf
Vice President, Commercial
Nielsen Bio

4:00 Why Some Dermatology Programs Become Billion-Dollar Franchises While Others Disappear



John Armstrong
Head of Healthcare Banking
WestPark Capital

4:30 Investor Panel: Where Is Dermatology Investment Heading Beyond the Dupixent Era?

- Assessing which indications offer the greatest unmet need and commercial opportunity, guiding portfolio prioritisation, to maximize long-term value creation
- Debating whether the next wave of investment will favour multispecifics, degraders, microbiome therapeutics, AI-designed biologics or engineered-cell approaches, clarifying emerging platform trends, to understand where capital is flowing
- Understanding how investors evaluate differentiation across efficacy, safety, dosing and translational confidence, aligning development strategy with market expectations, to build fundable and partnerable dermatology assets



Hyun Kim
Senior Vice President, Clinical Development
AOBiome

5:00 Chair's Closing Remarks & End of Conference



Harald Schnidar
Chief Executive Officer
Scarletred

Partnership Opportunities

Your Global Platform to Build Strategic Relationships Across the Dermatology Drug Development Ecosystem

As dermatology pipelines expand beyond Atopic Dermatitis and Psoriasis into Hidradenitis Suppurativa, Vitiligo, Acne, Alopecia Areata, Prurigo Nodularis, Molluscum Contagiosum and rare inflammatory skin diseases, developers face growing challenges around translational confidence, target validation, biomarker strategy, clinical trial execution and therapeutic differentiation.

To address these hurdles, biopharma teams are actively seeking partners that can improve preclinical predictability, accelerate recruitment, standardize endpoints, generate deeper biological insights and optimize delivery strategies.

The **10th Dermatology Drug Development Summit** offers a unique opportunity to engage directly with discovery, translational, clinical, medical affairs and commercial leaders looking for innovative solutions to advance the next generation of dermatology therapeutics.



Direct Access to Decision-Makers Shaping the Future of Dermatology Drug Development

Engage with 90+ senior discovery, translational, clinical development, medical affairs and commercial leaders from dermatology-focused pharma and biotech companies actively advancing next-generation therapies. As organizations race to differentiate against established market leaders and secure investment for emerging assets, position your solutions alongside the teams tackling target validation, biomarker development, dosing optimization, clinical execution and commercialization challenges across the dermatology pipeline.



Supporting the Industry's Most Pressing Development Challenges

Built from extensive research with dermatology drug developers, the agenda focuses on the challenges currently slowing pipeline progression. From improving translational confidence through biomarkers and patient stratification, to advancing topical and systemic delivery technologies, reducing operational variability in global studies, strengthening evidence generation for investors, and differentiating therapies beyond the Dupixent era, attendees are actively seeking external expertise to accelerate development timelines and reduce risk. Demonstrate how your capabilities can help sponsors overcome critical bottlenecks and bring the next generation of dermatology therapeutics to market faster.





Visibility in High-Trust, High-Signal Discussions

Interactive workshops, panels, and roundtables are designed for interaction rather than passive listening to help you build credibility, long-term relationships, and inbound opportunities that rarely emerge from large trade-show formats.


“ Good opportunities to network throughout the event and nice mix of relevant presentations ”

Vice President,
TFS HealthScience

Seniority of Attendees



Type of Companies Attending



*Statistics Taken from the 9th Dermatology Drug Development Summit

Get Involved



Oliver Smare
Senior Partnerships Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

2026 Partners



Lead Partner - Scarletred

SCARLETRED is the worldwide leader in mobile, standardized skin imaging and AI-powered objective skin analysis. We develop and deliver certified medical device

systems integrated in clinical trials worldwide – for biopharma, biotech, cosmetic, and aesthetic companies as well as governmental and healthcare institutions.

Our medical-certified, EU-GDPR- and ICH-GCP-compliant Software as a Medical Device (SaMD) Scarletred®Vision, powered by the agentic AI ARORA®, is the first digital solution addressing lacking standardization and subjective skin assessment in pre-clinical, clinical (Phase I-III) and post-marketing studies (Phase IV).

The highly scalable software platform works independently from infrastructure and location, available on iOS and Android devices worldwide, enabling onsite as well as home-based documentation, quantification, and monitoring of dermatologic disease-related skin data, as well as digital skin clinimetry and endpoints of skin drug-related effects.

Scarletred®Vision reduces development time and opportunity costs in clinical R&D projects. Our digital products and services are delivered worldwide from our offices in Europe and the USA via flexible Software as a Service (SaaS) agreements.

www.scarletred.com



Expertise Partner - CHDR

At CHDR, we take a multi-faceted approach to pharmacology and dermatology. We investigate treatments for dermatological conditions such as psoriasis, eczema, allergic reactions, and inflammation, utilising advanced methods and biomarkers to objectively monitor clinical responses. Through these approaches, we can measure the effects of transdermal and intradermal drugs on the skin. Additionally, we study systemic conditions by evaluating skin responses, for example by measuring nerve fibre conduction, surface blood vessels, and local inflammation. Moreover, we are actively exploring ways to enhance wound healing.

www.chdr.nl/therapeutic-areas/dermatology



Innovation Partner – QuantifiCare

QuantifiCare is an Imaging CRO specialized in the management and analysis of 2D and 3D digital images in Phase I-IV multicenter and decentralized trials. With over 20 years of experience in clinical research and medical image processing, QuantifiCare has developed a strong expertise across the fields of dermatology, aesthetics, wound care and oncology. The company operates internationally from its offices in the USA, Europe, South America and Asia.

www.quantificare.com



Innovation Partner - QIMA Life Sciences

QIMA Life Sciences partners with life sciences innovators to accelerate research and streamline drug development, with deep expertise in dermatology and immunology and inflammation. We provide end-to-end support from early discovery through clinical stages, advancing programs with a 20,000-sample primary cell bank, proprietary clinical bioanalysis, and access to ex vivo patient biopsies. This integrated approach delivers the scientific evidence needed to move innovative therapies forward with confidence.

www.qima-lifesciences.com

■ This conference was an incredible opportunity to connect with key players in the dermatology industry. It was inspiring to meet so many industry leaders and learn about the innovative treatments currently in development. We're already looking forward to returning next year! ■

Business Development Manager, **Symbio**

2026 Partners



Innovation Partner - Legit Health

Legit.Health is an AI-powered platform certified as a medical device that automates clinical endpoint collection in dermatology trials. Using clinical photographs, it objectively measures conditions like atopic dermatitis, psoriasis, and hidradenitis suppurativa (HS) with validated scores such as EASI, PASI and IHS4. Investigators receive instant objective severity calculations, reducing workload, while sponsors can monitor data in real time. Our validated algorithms ensure consistent, standardized assessments—addressing data quality challenges and supporting reliable drug development in dermatology.

www.legit.health



Exhibition Partner - Therapeutics (The Dermatology CRO)

San Diego based, Therapeutics, Inc., The Dermatology CRO was founded in 1997. Approximately 90% of our activities are focused on developing dermatology products. TI is the only dermatology focused CRO that provides all services required to move a product concept through nonclinical and clinical stages to FDA approval. During the last 5 years: TI managed >12,000 subjects in >80 clinical studies and filed 18 INDs and IDEs in a variety of drug, device and biologic programs.

www.therapeuticsinc.com



Exhibition Partner - Dow Development

Dow Development Laboratories' core expertise is in the development, manufacture, and testing of topical dermatological drug products for clinical use. Products are designed to be iseasecompatible, cosmetically elegant and physically and chemically stable. Our formulation, analytical, production, quality, and clinical labeling teams have decades of experience moving products quickly toward regulatory approval. DDL works seamlessly with its parent company Symbio Proinnovera, a global CRO with decades of success in conducting clinical trials, to rapidly advance dermatological programs through all stages of clinical development.

www.dowdevelopmentlabs.com



Event Partner – Canfield

Canfield Scientific is the global leader providing custom skin imaging systems and services for pharmaceutical, biotech, and medical device companies to demonstrate efficacy in clinical trials worldwide. Canfield's patented technology includes multi-spectral and multi-modal 2D and 3D imaging systems, cloud based digital asset management, and applications for objective analysis within compliant and validated systems. ISO 27001 certification confirms Canfield's Information Security Management System meets the highest international standards.

www.canfieldsci.com



Event Partner - CPL

CPL's team of scientists is experienced in employing topical testing techniques such as IVRT, IVPT and skin-model-based testing – vital parameters in the development and monitoring of semi-solid topical drug products. Our Skin Lab is eager to support your testing needs for the development of topical and generic semi-solid drug products.

www.cplltd.com/services/skin-lab



Event Partner - Nuvisan

NUVISAN is an established CRO whose expertise is bolstered by the pharmaceutical heritage of leading dermatology companies. We provide integrated services along the drug discovery and development value chain to support your projects in dermatology with flexible approaches for both start-ups and big pharma. From Drug Substance to Drug Product, our development capabilities cover all steps required for conceiving dermatological therapeutics as well as conducting targeted clinical studies.

www.nuvisan.com

Ready to Register?

 www.dermatology-drugdevelopment.com/take-part/register/

 register@hansonwade.com

 +1 617 455 4188

3 Reasons to Attend:



DISCOVER how leading dermatology innovators are advancing novel targets, biomarkers and next-generation therapeutic modalities to overcome the limitations of current standards of care.



BUILD your understanding of the latest strategies to optimize dosing regimens, improve translational success and strengthen clinical development programs across inflammatory skin diseases.



ENGAGE with senior discovery, preclinical, clinical, medical affairs, commercial and investment leaders shaping the future of dermatology drug development.

Drug Developer Pricing*	Register & Pay By Friday, July 17	On The Door
Full Access Package (Conference + Pre-Conference Workshop Day)	\$3,397 (Save \$1000)	\$4,397
Conference Only	\$2,599 (Save \$500)	\$3,099
Academic & Research Institute Pricing**	Register & Pay By Friday, July 17	On The Door
Full Access Package (Conference + Pre-Conference Workshop Day)	\$2,797 (Save \$1000)	\$3,797
Conference Only	\$2,199 (Save \$500)	\$2,699
Service & Solutions Provider Pricing***	Register & Pay By Friday, July 17	On The Door
Full Access Package (Conference + Pre-Conference Workshop Day)	\$4,397 (Save \$1000)	\$5,397
Conference Only	\$3,399 (Save \$500)	\$3,899

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please email info@hansonwade.com if you have any questions

**To qualify for academic and research rate you must be full time academic. Please email info@hansonwade.com if you have any questions

***If you are a solution or service provider, have you considered sponsoring this event? Sponsorship includes multiple passes at a discounted rate. Inquire to learn more*

Please note, this is subject to change at any time without prior notice.

Group Discounts

10% discount
2 passes

15% discount
3 passes

20% discount
4+ passes


Please note that discounts are only valid when two or more delegates from one company book and pay at the same time. Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate. Contact: info@hansonwade.com

VENUE:

The Colonnade Boston

120 Huntington Ave | Boston, MA 02116

www.colonnadehotel.com



TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Ltd is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Conferences Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom